Jeffrey M. Witkin - Concepedia

Author

Jeffrey M. Witkin

Also Known As

J M WITKIN, J M Witkin, J. M. WITKIN, J. M. Witkin, J.M Witkin, J.M. Witkin, Jane Witkin, Jeffrey M. Witkin, Jeffrey M Witkin, Jeffrey M. Witkin

544

Publications

9.7K

Citations

H-Index

117

Concepts

All Affiliations

Eli Lilly (United States)National Institute on Drug Abuse National Institutes of Health University of Wisconsin–Milwaukee Walter Reed Army Institute of Research

About

Jeffrey M. Witkin is an author at Eli Lilly (United States) specializing in medicine, neuropharmacology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	98	3.9K
2	Health Sciences	10	11	465
3	Engineering	1	1	63
4	Natural Sciences	1	1	22
5	Public Health	1	1	25

Jeffrey M. Witkin

155

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions Eleni T. Tzavara, Richard J. Davis, Kenneth W. Perry, British Journal of Pharmacology	2003	269
Allosteric modulation of the muscarinic M <sub>4</sub> receptor as an approach to treating schizophrenia Wai‐Yee Chan, David L. McKinzie, Suchira Bose, Proceedings of the National Academy of Sciences	2008	233
Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac) Per Svenningsson, Eleni T. Tzavara, Jeffrey M. Witkin, Proceedings of the National Academy of Sciences	2002	229
Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. Jeffrey M. Witkin, David E. Nichols, Philip Terry, Journal of Pharmacology and Experimental Therapeutics	1991	178
Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice Xia Li, Anne B. Need, Melvyn Baez, Journal of Pharmacology and Experimental Therapeutics	2006	160
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT<sub>6</sub>Receptor Stimulation Per Svenningsson, Eleni T. Tzavara, Hongshi Qi, Journal of Neuroscience	2007	157
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders Linda M. Rorick‐Kehn, Bryan G. Johnson, Karen M. Knitowski, Psychopharmacology Molecular PharmacologyPsychoactive DrugPsychiatric DisordersPsychiatryMedicine	2007	156
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders Linda M. Rorick‐Kehn, Jeffrey M. Witkin, Michael A. Statnick, Neuropharmacology Psychoactive DrugPsychiatryFunctional SelectivityMedicineAnimal Models	2013	148
Decreases in nestlet shredding of mice by serotonin uptake inhibitors: Comparison with marble burying Xia Li, Denise Morrow, Jeffrey M. Witkin Life Sciences Serotonin Uptake InhibitorsMedicinePhysiologyPsychopharmacologyMarble Burying	2005	135
Anticonvulsant and Behavioral Effects of Neuroactive Steroids Alone and in Conjunction with Diazepam Maciej Gąsior, Richard B. Carter, Stephen R. Goldberg, Journal of Pharmacology and Experimental Therapeutics	1997	131

Page 1